Focal ablation outcomes for prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This study looks at how well a targeted procedure (“focal ablation,” which destroys only the cancer area) works for certain men with prostate cancer that is limited to the prostate. It may help doctors understand which people benefit most and what outcomes to expect.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have prostate cancer confirmed by prostate biopsy (prostate tissue sample).
- Your cancer is either new/confirmed prostate cancer, or a local recurrence in the prostate area only.
- Scans show the cancer has not spread beyond the prostate to nearby areas or other organs (no metastatic disease).
- You are between 18 and 90 years old, and you have an expected life expectancy of more than 1 year.
- You can understand the study and sign written informed consent.
- Your prostate shape/structure allows the focal ablation procedure to be done (no anatomy that prevents it).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a laser treatment that targets only the cancerous part of the prostate. It may be an option for men with intermediate-risk prostate cancer who do not want their entire prostate removed.
This study is tracking men who choose focal therapy (a targeted treatment) for their localized prostate cancer. It aims to learn how well this treatment works and how it affects quality of life.
This study looks at outcomes after “focal therapy,” a type of treatment that targets only part of the prostate, for people with newly diagnosed or returning prostate cancer. It may help researchers understand how well this targeted approach works and for whom.
This study collects data on men with early, low-risk prostate cancer who choose to have a targeted ultrasound treatment called HIFU (High-Intensity Focused Ultrasound). It looks at how well this treatment works and how men recover.
This registry tracks men with early-stage prostate cancer who choose focal therapy—a targeted treatment that destroys only the cancer area while preserving healthy prostate tissue. The study helps doctors understand how well this approach works and its safety.
This study tests a targeted treatment for prostate cancer that aims to treat only the cancer while sparing healthy tissue. It may be an option for men with low to medium risk prostate cancer.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.